Cagrilintide dosage calculator
Enter a vial and a dose and this returns the concentration, the volume and the syringe units. Underneath it, the same arithmetic worked out in advance for common vials, and the doses published studies of Cagrilintide actually used, every one quoted and cited. It converts numbers. It does not suggest what to take.
Work out concentration and what to draw
Two divisions, both shown. Concentration = mass in the vial ÷ diluent volume. Volume to draw = mass you want ÷ that concentration. Syringe units are that volume × the units per millilitre on your syringe's own scale.
Worked example: 5 mg in 2 mL is 2,500 mcg/mL, so 250 mcg is 0.1 mL, which is 10 units on a U-100 syringe and 4 units on a U-40. The scale is printed on the barrel; reading a U-40 syringe as if it were U-100 is a two-and-a-half-fold error.
Cagrilintide reconstitution chart
Units on a standard U-100 insulin syringe, where 100 units is 1 mL. The rows are the absolute doses quoted in studies of Cagrilintide, from 2.4 mg to 30 mg, so this chart is specific to this compound rather than a generic ladder. More diluent means more units for the same dose, which is easier to measure accurately and empties the vial no faster.
| Dose | 1 mL diluent (2,000 mcg/mL) | 2 mL diluent (1,000 mcg/mL) | 3 mL diluent (667 mcg/mL) |
|---|---|---|---|
| 2.4 mg | 120 >1 mL | 240 >1 mL | 360 >1 mL |
| 4 mg | 200 >1 mL | 400 >1 mL | 600 >1 mL |
| 5 mg | 250 >1 mL | 500 >1 mL | 750 >1 mL |
| 15 mg | 750 >1 mL | 1,500 >1 mL | 2,250 >1 mL |
| 30 mg | 1,500 >1 mL | 3,000 >1 mL | 4,500 >1 mL |
| Dose | 1 mL diluent (5,000 mcg/mL) | 2 mL diluent (2,500 mcg/mL) | 3 mL diluent (1,667 mcg/mL) |
|---|---|---|---|
| 2.4 mg | 48 | 96 | 144 >1 mL |
| 4 mg | 80 | 160 >1 mL | 240 >1 mL |
| 5 mg | 100 | 200 >1 mL | 300 >1 mL |
| 15 mg | 300 >1 mL | 600 >1 mL | 900 >1 mL |
| 30 mg | 600 >1 mL | 1,200 >1 mL | 1,800 >1 mL |
| Dose | 1 mL diluent (10,000 mcg/mL) | 2 mL diluent (5,000 mcg/mL) | 3 mL diluent (3,333 mcg/mL) |
|---|---|---|---|
| 2.4 mg | 24 | 48 | 72 |
| 4 mg | 40 | 80 | 120 >1 mL |
| 5 mg | 50 | 100 | 150 >1 mL |
| 15 mg | 150 >1 mL | 300 >1 mL | 450 >1 mL |
| 30 mg | 300 >1 mL | 600 >1 mL | 900 >1 mL |
Read a figure off this chart only if it matches the vial in front of you. A vial labelled a different strength, or reconstituted with a different volume, gives a different number for the same dose, and that is the single most common way these calculations go wrong.
Doses in published studies of Cagrilintide
Each row is quoted from a paper in this compound's source ledger and carries the kind of evidence it came from. 6 of 6 come from human studies; the rest are animal or laboratory work.
| Evidence | Dose as the paper states it | Source |
|---|---|---|
| Human clinical trial | Randomized controlled trial, humans, 2026: doses stated in the abstract: 2.4 mg. The phase 3a, 68-week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m 2 , or ≥ 27 kg/m 2 with ≥ 1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus… | pmid-42503495 |
| Human clinical trial | Randomized controlled trial, humans, n=99, 2026: doses stated in the abstract: 2·4 mg. Eligible participants were randomly assigned to receive subcutaneous zalfermin 7·5 mg plus subcutaneous semaglutide 2·4 mg, zalfermin 15 mg plus semaglutide 2·4 mg, zalfermin 30 mg plus semaglutide 2·4 mg, zalfermin 30 mg, semaglutide 2·4 mg,… | pmid-42456707 |
| Human clinical trial | Randomized controlled trial, humans, n=90, 2026: doses stated in the abstract: 2·4 mg; 1·0 mg. Adults with type 2 diabetes (glycated haemoglobin [HbA 1c ] 7·0-10·5%) receiving stable once per day basal insulin with or without metformin were randomly assigned (2:2:1:1) to once per week subcutaneous cagrilintide 2·4 mg plus semaglutide… | pmid-42251856 |
| Human clinical trial | Randomized controlled trial, humans, n=62, 2026: doses stated in the abstract: 2·4 mg; 1·0 mg. Adults aged 18 years or older with type 2 diabetes inadequately controlled with diet and exercise were randomly assigned (2:1:2:1) to receive once-weekly subcutaneous cagrilintide 2·4 mg plus semaglutide 2·4 mg (cagrilintide-semaglutide [2·4… | pmid-42251860 |
| Human clinical trial | Randomized controlled trial, humans, n=603, 2026: doses stated in the abstract: 2·4 mg; 1·0 mg. Participants aged 18 years or older with inadequately controlled type 2 diabetes (HbA 1c 7·0-10·5% [53-91 mmol/mol]) receiving metformin with or without an SGLT2 inhibitor, and a BMI of 25 kg/m 2 or more, were randomly assigned… | pmid-42251859 |
| Human clinical trial | Randomized controlled trial, humans, n=164, 2026: doses stated in the abstract: 2·4 mg. We assessed the efficacy and safety of a fixed-dose combination of cagrilintide 2·4 mg and semaglutide 2·4 mg versus semaglutide 2·4 mg for weight management in an east Asian population. | pmid-42009015 |
Escalation schedules used in studies
Where a trial raised the dose over time rather than starting at the target, this is what it did. The starting dose is often the part that decides tolerability, which is why it is reported here and not only the dose the trial finished on.
- Randomized controlled trial, humans, n=164, 2026: Participants were randomly assigned (1:1) to once-weekly subcutaneous injections of cagrilintide-semaglutide or semaglutide (both escalated to 2·4 mg), plus lifestyle intervention, for 68 weeks. pmid-42009015
- Randomized controlled trial, humans, n=53, 2024: This was a double-blind study (NCT05804162) in which healthy participants were randomized to cagrilintide, administered as a once-weekly subcutaneous injection dose escalated to 4.5 mg, or a placebo. pmid-39279639
- Randomized controlled trial, humans, n=31, 2023: Adults with type 2 diabetes and a BMI of 27 kg/m 2 or higher on metformin with or without an SGLT2 inhibitor were randomly assigned (1:1:1) to once-weekly subcutaneous CagriSema, semaglutide, or cagrilintide (all escalated to 2·4 mg). pmid-37364590
- Randomized controlled trial, humans, n=12, 2021: In each cohort, the doses of cagrilintide and semaglutide were co-escalated in 4-week intervals to the desired dose over 16 weeks, participants were treated at the target dose for 4 weeks, and then followed up for 5 weeks. pmid-33894838
How long studies ran, and how far a vial goes
A vial lasts for a number of draws, not a number of weeks: divide the mass in the vial by the mass per draw and round down, which the vial planner does. How long that represents depends on frequency. For context, these are the durations studies of Cagrilintide actually ran for.
- Randomized controlled trial, humans, n=99, 2026: durations stated: 52 weeks. Eligible participants were randomly assigned to receive subcutaneous zalfermin 7·5 mg plus subcutaneous semaglutide 2·4 mg, zalfermin 15 mg plus semaglutide 2·4 mg, zalfermin 30 mg plus semaglutide 2·4 mg, zalfermin 30 mg, semaglutide 2·4 mg, cagrilintide 2·4… pmid-42456707
- Randomized controlled trial, humans, n=90, 2026: durations stated: 40 weeks. Adults with type 2 diabetes (glycated haemoglobin [HbA 1c ] 7·0-10·5%) receiving stable once per day basal insulin with or without metformin were randomly assigned (2:2:1:1) to once per week subcutaneous cagrilintide 2·4 mg plus semaglutide 2·4 mg (hereafter… pmid-42251856
- Randomized controlled trial, humans, n=62, 2026: durations stated: 18 years; 40 weeks. Adults aged 18 years or older with type 2 diabetes inadequately controlled with diet and exercise were randomly assigned (2:1:2:1) to receive once-weekly subcutaneous cagrilintide 2·4 mg plus semaglutide 2·4 mg (cagrilintide-semaglutide [2·4 mg… pmid-42251860
- Randomized controlled trial, humans, n=603, 2026: durations stated: 18 years; 68 weeks. Participants aged 18 years or older with inadequately controlled type 2 diabetes (HbA 1c 7·0-10·5% [53-91 mmol/mol]) receiving metformin with or without an SGLT2 inhibitor, and a BMI of 25 kg/m 2 or more, were randomly assigned (8:8:2:8:8:1:1) to… pmid-42251859
- Randomized controlled trial, humans, n=1,206, 2025: durations stated: 68 weeks. In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly… pmid-40544432
How Cagrilintide was given
The route changes what a dose means. The same number given intravenously and subcutaneously is not the same exposure.
- Randomized controlled trial, humans, n=99, 2026: administration by subcutaneous route reported. Eligible participants were randomly assigned to receive subcutaneous zalfermin 7·5 mg plus subcutaneous semaglutide 2·4 mg, zalfermin 15 mg plus semaglutide 2·4 mg, zalfermin 30 mg plus semaglutide 2·4 mg, zalfermin 30 mg, semaglutide 2·4 mg,… pmid-42456707
- Randomized controlled trial, humans, n=90, 2026: administration by subcutaneous route reported. Adults with type 2 diabetes (glycated haemoglobin [HbA 1c ] 7·0-10·5%) receiving stable once per day basal insulin with or without metformin were randomly assigned (2:2:1:1) to once per week subcutaneous cagrilintide 2·4 mg plus semaglutide… pmid-42251856
- Randomized controlled trial, humans, n=62, 2026: administration by subcutaneous route reported. Adults aged 18 years or older with type 2 diabetes inadequately controlled with diet and exercise were randomly assigned (2:1:2:1) to receive once-weekly subcutaneous cagrilintide 2·4 mg plus semaglutide 2·4 mg (cagrilintide-semaglutide [2·4… pmid-42251860
- Randomized controlled trial, humans, n=603, 2026: administration by subcutaneous route reported. Participants aged 18 years or older with inadequately controlled type 2 diabetes (HbA 1c 7·0-10·5% [53-91 mmol/mol]) receiving metformin with or without an SGLT2 inhibitor, and a BMI of 25 kg/m 2 or more, were randomly assigned… pmid-42251859
- Randomized controlled trial, humans, n=164, 2026: administration by subcutaneous route reported. Participants were randomly assigned (1:1) to once-weekly subcutaneous injections of cagrilintide-semaglutide or semaglutide (both escalated to 2·4 mg), plus lifestyle intervention, for 68 weeks. pmid-42009015
- Randomized controlled trial, humans, n=53, 2024: administration by subcutaneous route reported. This was a double-blind study (NCT05804162) in which healthy participants were randomized to cagrilintide, administered as a once-weekly subcutaneous injection dose escalated to 4.5 mg, or a placebo. pmid-39279639
Questions people ask
- How many units is 2.4 mg of Cagrilintide?
- It depends entirely on how the vial was reconstituted. In a 5 mg vial with 2 mL of diluent it is 96 units on a U-100 syringe; with 1 mL it is 48. The chart above gives the rest.
- Does adding more diluent waste the peptide?
- No. The mass in the vial does not change. More diluent spreads the same mass through more liquid, so each dose is a larger, easier-to-measure volume and the vial yields exactly as many doses as before.
- Why does this page not recommend a dose?
- Because a dose is a clinical decision rather than a division. It depends on why someone is taking something, what else they take and how their kidneys and liver are working, none of which is knowable from a number typed into a box.
- Where do the doses in the table come from?
- Each is quoted from a specific paper indexed in Europe PMC, linked in the source column, and labelled with the kind of study it came from. The full evidence is on the Cagrilintide record.
What this calculator will not do
It will not take a body weight and return a milligram figure, and it will not tell you how often to draw. The table above is the published record, not a menu. A dose that appeared in a trial appeared under supervision, with monitoring, in people selected for that trial.
Other calculators
- Generic reconstitution calculatorThe same arithmetic, without a compound attached
- Unit convertermg, mcg, ng and syringe units
- Vial plannerDraws per vial and how long it lasts
- All compound calculatorsEvery compound with published dose figures